title: [Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis].
abstract: OBJECTIVE
  The aim of our study was to evaluate the tolerance of two inhaled hypertonic saline solutions (HS) in patients with cystic fibrosis.
  
  
  METHODS
  Eighty one cystic fibrosis (CF) patients (44 males; mean age 23.63 years) inhaled 5 ml of 7% inhaled HS solution and, in those patients who did not tolerate HS, we evaluated the tolerance of a 7% HS (at dose of 5 ml) added to 0.1% hyaluronic acid at least twenty-four hours later.
  
  
  RESULTS
  Twenty one (26%) patients did not tolerate the HS solution immediately after its inhalation. Cough was the most common symptom. Patients over 18 years of age showed worse tolerance to HS than patients younger than 18 years of age. Those patients that did not tolerate HS had a worse lung function that the ones that showed good tolerance. Eighty-one percent of patients who did not tolerate the HS alone tolerated well the HS with hyaluronic acid.
  
  
  CONCLUSIONS
  CF patients cannot tolerate inhaled HS immediately after nebulisation. Patients over 18 years and those with worse lung function tolerate HS worst. Hyaluronate acid added to 7% HS solution improves the tolerability.
authors.affiliation: Unidad de Fibrosis Quística, Hospital Ramón y Cajal, Madrid, España. lmaiz.hrc@salud.madrid.org
authors.forename: Luis
authors.initials: L
authors.lastname: Máiz Carro
authors.forename: Adelaida
authors.initials: A
authors.lastname: Lamas Ferreiro
authors.forename: Marta
authors.initials: M
authors.lastname: Ruiz de Valbuena Maiz
authors.forename: Carolin
authors.initials: C
authors.lastname: Wagner Struwing
authors.forename: Gustavo
authors.initials: G
authors.lastname: Gabilondo Álvarez
authors.forename: Lucrecia
authors.initials: L
authors.lastname: Suárez Cortina
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002648:Child; D003371:Cough / Q000139:chemically induced*; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000523:psychology; D004417:Dyspnea / Q000139:chemically induced; D005100:Expectorants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D010342:Patient Acceptance of Health Care; D010612:Pharyngitis / Q000139:chemically induced; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014797:Vital Capacity; D055815:Young Adult
chemical_list: D005100:Expectorants; D012462:Saline Solution, Hypertonic; D006820:Hyaluronic Acid